Treatment
Capecitabine clinical trials
We’re tracking 278 recruiting studies that include Capecitabine, each written for real people, not researchers, below.
Recruiting studies
- NCT05360277RecruitingPhase 2
Maintenance immunotherapy and chemo after surgery for metastatic colon cancer
This Phase 2 trial studies tislelizumab plus capecitabine given after surgery to help prevent metastatic colorectal cancer from coming back. It may be an option if you recently had surgery that removed visible disease and you have good overall health.
Guangzhou, GuangdongAges 18–80 - NCT01935778RecruitingPhase 3
Extra chemo after stomach cancer surgery: compare two drug plans
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
SeoulAges 20–75 - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06313567RecruitingPhase 3
Metronomic capecitabine for stage III stomach cancer
This trial tests a low-dose, frequent regimen of the chemotherapy drug capecitabine (taken as a pill) to see if it can help prevent stage III stomach cancer from coming back after surgery. It's for people who have had their stomach cancer completely removed with a specific type of lymph node dissection.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07790445RecruitingPhase 4
Adjuvant chemotherapy for bile duct cancer after surgery
This study tests whether giving chemotherapy directly into the liver (HAIC) plus an oral chemo pill (capecitabine) after surgery helps prevent bile duct cancer from coming back, compared to just the pill. It's for people who recently had their cancer completely removed.
Zhengzhou, HenanAges 18 years+ - NCT06560528RecruitingPhase 2
Drug combo before & after surgery for HER2+ stomach cancer
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07692152RecruitingPhase 3
Immunotherapy vs. chemo for MS anal cancer trial
This trial tests sintilimab (a type of immunotherapy) against mitomycin plus chemotherapy with radiation for anal cancer that hasn't spread. It aims to find a better treatment with fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07692750RecruitingPhase 1/Phase 2
IBI343 plus chemo for advanced pancreatic cancer
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
Hangzhou, ZhejiangAges 18 years+ - NCT07683949Enrolling by invitationPhase 1/Phase 2
Capecitabine plus lenvatinib for advanced colorectal cancer
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
Seongnam-si, Out of USAges 19–99 - NCT07679399RecruitingPhase 2
New combo therapy vs capecitabine for biliary tract cancer after surgery
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
BeijingAges 18–75 - NCT05063136RecruitingPhase 3
Metronomic capecitabine with hormone therapy after breast cancer
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
Zhengzhou, HenanAges 18–70 - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT06700382Recruiting
Capecitabine for TNBC after incomplete response
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
Beijing, Beijing MunicipalityAges Any age - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT07584135RecruitingPhase 3
JS107, Toripalimab, and Chemotherapy for Advanced Stomach Cancer
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18 years+ - NCT06602167Recruiting
Acupuncture and acupressure to prevent hand-foot syndrome from capecitabine
This trial tests if electroacupuncture combined with self-administered acupressure can prevent hand-foot syndrome, a common side effect of the chemotherapy drug capecitabine. It is for people with gastrointestinal or breast cancer who are starting capecitabine for the first time.
Xining, QinghaiAges 18–85 - NCT06405490RecruitingPhase 2
Chemo plus immunotherapy for first-line advanced pancreatic cancer
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06765252Recruiting
How gene differences affect capecitabine side effects
This study looks at how genetic differences in Egyptian people with breast or colorectal cancer might affect the side effects of the chemotherapy drug capecitabine. The goal is to understand why some people have more side effects than others.
Shibīn al Kawm, MenoufiaAges 18 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT07462143RecruitingPhase 2/Phase 3
New drug plus chemo for advanced colorectal cancer
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06685289RecruitingPhase 2
Donafenib and capecitabine after surgery for biliary cancer with high risk of return
This trial tests whether taking donafenib and capecitabine pills after surgery can help prevent biliary cancer from coming back in people who have a high risk of recurrence. It is for patients whose cancer was completely removed but had certain features that make recurrence more likely.
Nanjing, JiangsuAges 18–75
Common questions
- Are there clinical trials studying Capecitabine?
- Yes. Clin2 currently lists 278 recruiting studies that include Capecitabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Capecitabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Capecitabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Capecitabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.